HELP TAKE THE
FIRE OUT OF
AUTOINFLAMMATORY
DISEASE
ILARIS is the only biologic indicated to treat
7 autoinflammatory diseases across Still’s disease
and a range of Periodic Fever Syndromes (PFS)
- •Still’s disease: SJIA and AOSD
- •PFS: FMF, HIDS/MKD, TRAPS, CAPS (FCAS and MWS)
ILARIS is the only biologic indicated to treat
7 autoinflammatory diseases across Still’s disease
and a range of Periodic Fever Syndromes (PFS)
- •Still’s disease: SJIA and AOSD
- •PFS: FMF, HIDS/MKD, TRAPS, CAPS (FCAS and MWS)
ILARIS is dosed once monthly in Still’s disease, FMF, HIDS/MKD, and TRAPS and once every 2 months in CAPS (FCAS and MWS)1
ILARIS selectively targets IL-1β—a critical driver of autoinflammatory disease to block inflammatory signaling1-5
ILARIS offers dedicated and dependable support for patients throughout their ILARIS treatment journey
Interleukin 1 beta (or IL-1β) is a critical driver of autoinflammatory diseases such as Still’s disease (systemic idiopathic juvenile arthritis and adult-onset Still’s disease) and periodic fever syndromes (eg, familial Mediterranean fever, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, tumor necrosis factor receptor–associated periodic syndrome, cryopyrin-associated periodic syndromes). IL-6, IL-18, and TNF also play a role in autoinflammatory diseases. IFN-γ and IL-17 are key drivers of autoimmune diseases.2-8 Interleukin 1 beta (or IL-1β) is primarily induced and actively produced by immune cells under disease conditions.9,10 In certain autoinflammatory diseases, there is an excessive release of activated interleukin 1 beta (or IL-1β).3,5,11 This overabundance can cause an inflammatory cascade in Still’s disease and periodic fever syndromes, driving fever and systemic inflammation.5,9,11-17 Interleukin 1 beta (or IL-1β) is one of the master mediators of autoinflammatory disease. The ILARIS (canakinumab) mechanism of action involves selective targeting of interleukin 1 beta (or IL-1β) to block inflammatory signaling.1
ILARIS (canakinumab) is a recombinant, human anti-human–IL-1β monoclonal antibody and the only IL-1β–specific inhibitor.1 ILARIS (canakinumab) is proven efficacious in 7 autoinflammatory diseases across Still’s disease and a range of periodic fever syndromes.1 Additionally, ILARIS (canakinumab) dosing is once monthly in Still’s disease, familial Mediterranean fever, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, and tumor necrosis factor receptor–associated periodic syndrome. ILARIS (canakinumab) is administered once every 2 months in cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome.1 The ILARIS support program—also known as ILARIS Companion—offers dedicated and dependable savings and support throughout the treatment journey for patients prescribed ILARIS.